Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect

Sorafenib resistance is a major challenge in the therapy for advanced hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms of HCC resistance to sorafenib remain unclear. Activator of thyroid and retinoid receptor (ACTR, also known as SRC‐3), overexpressed in HCC patients, pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Luyuan, Liu, Wenpeng, Xu, An, Ji, Quanbo, Ma, Yongfu, Tai, Yanhong, Wang, Yadong, Shen, Chuan, Liu, Ying, Wang, Tao, Han, Juqiang, Zhao, Caiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293092/
https://www.ncbi.nlm.nih.gov/pubmed/32279388
http://dx.doi.org/10.1111/cas.14412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293092/
https://www.ncbi.nlm.nih.gov/pubmed/32279388
http://dx.doi.org/10.1111/cas.14412

Ejemplares similares